Who owns FREELINE THERAPEUTICS HLDGS?

Tip: Access positions for across all investors

Analyze quarterly positions in Freeline Therapeutics Hldgs with up to 7 years of data, all consolidated into one spreadsheet

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Top investors of Freeline Therapeutics Hldgs stock

Who bought or sold FREELINE THERAPEUTICS HLDGS this quarter?

Fund or Company Name Shares Held Valued At Change in Shares As Of
Syncona Portfolio 22M $19M 0% Jun 2022
CHI Advisors 4.9M $4.2M 0% Jun 2022
Polygon Management 3.7M $4.1M 143% Mar 2022
Eventide Asset Management 3.6M $4.0M 3% Mar 2022
UBS Group 505k $535k 100% Mar 2022
Renaissance Technologies 265k $231k -41% Jun 2022
Morgan Stanley 185k $207k 100% Mar 2022
Harbor Capital Advisors 147k $129k 1% Jun 2022
Two Sigma Investments 133k $149k 223% Mar 2022
Federated Investors 60k $67k 50% Mar 2022
Values First Advisors 56k $49k 12% Jun 2022

Setup an alert

Want to be notified whenever an investor makes a significant change to their holdings of Freeline Therapeutics Hldgs?

Veritable 56k $63k 0% Mar 2022
SG Americas Securities 52k $45k -13% Jun 2022
Acadian Asset Management 27k $30k 100% Mar 2022
Two Sigma Advisers 24k $27k 100% Mar 2022
Aspire Private Capital 1.2k $999.960000 100% Mar 2022

Who sold out of Freeline Therapeutics Hldgs?

Fund or Company Name Date Sold Shares Held Valued At
Novo A/S Dec 2021 1.8M $3.5M
Wellington Management Company Dec 2021 440k $867k
Axa Dec 2021 284k $562k
Marshall Wace Dec 2021 111k $218k
Prospera Financial Services Mar 2022 35k $39k
Woodline Partners Dec 2021 26k $51k
Jpmorgan Chase & Co Mar 2022 664.00 $999.984000